Melatonin Improves Mood Status and Quality of Life and Decreases Cortisol Levels in Fibromyalgia

Abstract

Background:

Mood disturbances are implicated in the pathogenesis of fibromyalgia. The aim of this study was to assess the effect of different doses of melatonin on quality of life, mood status, pain, anxiety, and urinary cortisol levels in patients with fibromyalgia.

Methods:

After a 10-day baseline period for the collection of data about participants’ initial status, participants took different doses of melatonin for 10 consecutive days each, with placebo given during the 10 days either before or between melatonin doses. Participants’ moods, quality of life, and pain levels were assessed using the Fibromyalgia Impact Questionnaire (FIQ), a Numerical Pain Scale (NPS), the State-Trait Anxiety Test (STAI), a Visual Analog Scale (VAS), and the Short Form-36 Health Survey (SF-36). Urinary cortisol levels were measured using enzyme-linked immunoassay.

Results:

Doses of 9, 12, and 15 mg of melatonin were associated with decreases in the total score of the FIQ, NPS scores, and urinary cortisol levels. The State-Anxiety subscale of the STAI improved after the 12 mg dose. The scores on the VAS improved after the 9 mg dose. The dimensions evaluated in the SF-36 questionnaire improved after the 9 mg dose.

Conclusion:

Melatonin improved mood, anxiety levels, and quality of life while decreasing cortisol levels in patients with fibromyalgia.

Keywords

anxiety cortisol fibromyalgia melatonin mood status quality of life

Get full access to this article

View all access options for this article.

References

Acuña-Castroviejo

Escames

Reiter

R. J.

(2006). Melatonin therapy in fibromyalgia. Journal of Pineal Research, 40, 98–99.

Alonso

Regidor

Barrio

Prieto

Rodriguez

de la Fuente

(1998). Population reference values of the Spanish version of the Health Questionnaire SF-36. Medicina Clínica, 111, 410–416.

Bair

M. J.

Robinson

R. L.

Katon

Kroenke

(2003) Depression and pain comorbidity: A literature review. Archives of Internal Medicine, 163, 2433–2445.

Birtane

Uzunca

Taştekin

Tuna

(2007). The evaluation of quality of life in fibromyalgia syndrome: A comparison with rheumatoid arthritis by using SF-36 Health Survey. Clinical Rheumatology, 26, 679–684.

Burckhardt

C. S.

Clark

S. R.

Bennett

R. M.

(1991). The fibromyalgia impact questionnaire: Development and validation. Journal of Rheumatology, 18, 728–733.

Burckhardt

C. S.

Jones

K. D.

(2003). Adult measures of pain: The McGill Pain Questionnaire (MPQ), Rheumatoid Arthritis Pain Scale (RAPS), Short-Form McGill Pain Questionnaire (SF-MPQ), Verbal Descriptive Scale (VDS), Visual Analog Scale (VAS), and West Haven-Yale Multidisciplinary Pain Inventory (WHYMPI). Arthritis Care & Research, 49, 96–104.

Castaño

M. Y.

Garrido

Delgado-Adámez

Martillanes

Gómez

M. A.

Rodríguez

A. B.

(2018). Oral melatonin administration improves the objective and subjective sleep quality, increases 6-sulfatoxymelatonin levels and total antioxidant capacity in patients with fibromyalgia. Journal of Applied Biomedicine, 16,186–191.

Chen

W. W.

Zhang

Huang

W. J.

(2016). Pain control by melatonin: Physiological and pharmacological effects. Experimental and Therapeutic Medicine, 12, 1963–1968.

Citera

Arias

M. A.

Maldonado-Cocco

J. A.

Lázaro

M. A.

Rosemffet

M. G.

Brusco

L. I.

… Cardinalli

D. P.

(2000). The effect of melatonin in patients with fibromyalgia: A pilot study. Clinical Rheumatology, 19, 9–13.

10.

Cordero

M. D.

Alcocer-Gómez

Cano-García

F. J.

de Miguel

Sánchez-Alcázar

J. A.

Fernández

A. M. M.

(2010). Bajos valores de serotonina en suero se correlacionan con la gravedad de los síntomas de la fibromialgia. Medicina Clínica, 135, 644–646.

11.

Danilov

Kurganova

(2016). Melatonin in chronic pain syndromes. Pain and Therapy, 5, 1–17.

12.

De Zanette

S. A.

Vercelino

Laste

Rozisky

J. R.

Schwertner

Machado

C. B.

… Caumo

(2014). Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: A phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology, 15, 40.

13.

Fischer

Doerr

J. M.

Strahler

Mewes

Thieme

Nater

U. M.

(2016). Stress exacerbates pain in the everyday lives of women with fibromyalgia syndrome—The role of cortisol and alpha-amylase. Psychoneuroendocrinology, 63, 68–77.

14.

Giacomelli

Sernissi

Sarzi-Puttini

Di Franco

Atzeni

Bazzichi

(2013). Fibromyalgia: A critical digest of the recent literature. Clinical and Experimental Rheumatology, 31, S153–S157.

15.

Gonzalez

J. G.

del Teso Rubio

M. D. M.

Paniagua

C. N. W.

Criado-Alvarez

J. J.

Holgado

J. S.

(2015). Tratamiento sintomático y del dolor en fibromialgia mediante abordaje multidisciplinar desde Atención Primaria. Reumatología Clínica, 11, 22–26.

16.

Guerrero

J. M.

Carrillo-Vico

Lardone

P. J.

(2007). La melatonina. Investigación y Ciencia, 373, 30–38.

17.

Guillén-Riquelme

Buela-Casal

(2015). State–Trait Anxiety Inventory factorial structure for patients diagnosed with depression. Salud Mental, 38, 293–298.

18.

Hawker

Mian

Kendzerska

French

(2011). Measures of adult pain. Arthritis Care & Research, 63, 240–252.

19.

Hoffman

D. L.

Dukes

E. M.

(2008). The health status burden of people with fibromyalgia: A review of studies that assessed health status with the SF-36 or the SF-12. International Journal of Clinical Practice, 62, 115–126.

20.

Hussain

S. A. R.

Al-Khalifa

I. I.

Jasim

N. A.

Gorial

F. I.

(2011). Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research, 50, 267–271.

21.

Klante

Brinschwitz

Secci

Wollnik

Steinlechner

(1997). Creatinine is an appropriate reference for urinary sulphatoxymelatonin of laboratory animals and humans. Journal of Pineal Research, 23,191–197.

22.

Korszun

(2000). Sleep and circadian rhythm disorders in fibromyalgia. Current Rheumatology Reports, 2, 124–130.

23.

Mahdi

A. A.

Fatima

Das

S. K.

Verma

N. S.

(2011). Abnormality of circadian rhythm of serum melatonin and other biochemical parameters in fibromyalgia syndrome. Indian Journal of Biochemistry and Biophysics, 48, 82–87.

24.

McCormack

H. M.

David

J. D. L.

Sheather

(1988). Clinical applications of visual analogue scales: A critical review. Psychological Medicine, 18, 1007–1019.

25.

McLean

S. A.

Williams

D. A.

Harris

R. E.

Kop

W. J.

Groner

K. H.

Ambrose

… Clauw

D. J.

(2005). Momentary relationship between cortisol secretion and symptoms in patients with fibromyalgia. Arthritis & Rheumatology, 52, 3660–3669.

26.

Monterde

Salvat

Montull

Fernández-Ballart

(2004). Validación de la versión española del Fibromyalgia Impact Questionnaire. Revista Española de Reumatología, 31, 507–513.

27.

Pagano

Matsutani

L. A.

Ferreira

E. A. G.

Marques

A. P.

Pereira

C. A. D. B.

(2004). Assessment of anxiety and quality of life in fibromyalgia patients. São Paulo Medical Journal, 122, 252–258.

28.

Reiter

R. J.

(2003). Melatonin: Clinical relevance. Best Practice & Research: Clinical Endocrinology & Metabolism, 17, 273–285.

29.

Reiter

R. J.

Acuna-Castroviejo

Tan

D. X.

(2007). Melatonin therapy in fibromyalgia. Current Pain and Headache Reports, 11, 339–342.

30.

Reiter

R. J.

Tan

D. X.

Jou

M. J.

Korkmaz

Manchester

L. C.

Paredes

S. D.

(2008). Biogenic amines in the reduction of oxidative stress: Melatonin and its metabolites. Neuroendocrinology Letters, 29, 391–398.

31.

Revuelta

Segura

Tevar

J. P.

(2010). Depresión, ansiedad y fibromialgia. Revista de la Sociedad Española del Dolor, 17, 326–332.

32.

Salaffi

Sarzi-Puttini

Girolimetti

Atzeni

Gasparini

Grassi

(2009). Health-related quality of life in fibromyalgia patients: A comparison with rheumatoid arthritis patients and the general population using the SF-36 health survey. Clinical and Experimental Rheumatology, 27, 67–74.

33.

Toora

B. D.

Rajagopal

(2002). Measurement of creatinine by Jaffe’s reaction—Determination of concentration of sodium hydroxide required for maximum color development in standard, urine and protein free filtrate of serum. Indian Journal of Experimental Biology, 40, 352–354.

34.

Torres-Farfan

Richter

H. G.

Rojas-Garcia

Vergara

Forcelledo

M. L.

Valladares

L. E.

… Seron-Ferre

(2003). Melatonin receptor in the primate adrenal gland: Inhibition of adrenocorticotropin-stimulated cortisol production by melatonin. Journal of Clinical Endocrinology & Metabolism, 88, 450–458.

35.

Uçar

Sarp

Ü.

Karaaslan

Ö.

Irfan Gül

Tanik

Onur Arik

(2015). Health anxiety and depression in patients with fibromyalgia syndrome. Journal of International Medical Research, 43, 679–685.

36.

Van Praag

H. M

de Kloet

E. R.

Van Os

(2004). Stress, the brain and depression. Cambridge, England: Cambridge University Press.

37.

Vilagut

Ferrer

Rajmil

Rebollo

Permanyer-Miralda

Quintana

J. M.

… Alonso

(2005). El cuestionario de salud SF-36 español: Una década de experiencia y nuevos desarrollos [The Spanish SF-36 health questionnaire: A decade of experience and new developments]. Gaceta Sanitaria, 19, 135–150.

38.

Wilhelmsen

Amirian

Reiter

R. J.

Rosenberg

Gögenur

(2011). Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies. Journal of Pineal Research, 51, 270–277.

39.

Wolfe

Clauw

D. J.

Fitzcharles

M. A.

Goldenberg

D. L.

Katz

R. S.

Mease

… Yunus

M. B.

(2010). The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care & Research, 62, 600–610.